ATE260918T1 - Crf rezeptor-antagonisten und darauf bezogene methoden - Google Patents

Crf rezeptor-antagonisten und darauf bezogene methoden

Info

Publication number
ATE260918T1
ATE260918T1 AT01937614T AT01937614T ATE260918T1 AT E260918 T1 ATE260918 T1 AT E260918T1 AT 01937614 T AT01937614 T AT 01937614T AT 01937614 T AT01937614 T AT 01937614T AT E260918 T1 ATE260918 T1 AT E260918T1
Authority
AT
Austria
Prior art keywords
crf receptor
receptor antagonists
related methods
crf
pharmaceutically acceptable
Prior art date
Application number
AT01937614T
Other languages
English (en)
Inventor
Mustapha Haddach
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ATE260918T1 publication Critical patent/ATE260918T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT01937614T 2000-05-18 2001-05-18 Crf rezeptor-antagonisten und darauf bezogene methoden ATE260918T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20564900P 2000-05-18 2000-05-18
PCT/US2001/016326 WO2001087889A1 (en) 2000-05-18 2001-05-18 Crf receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE260918T1 true ATE260918T1 (de) 2004-03-15

Family

ID=22763066

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01937614T ATE260918T1 (de) 2000-05-18 2001-05-18 Crf rezeptor-antagonisten und darauf bezogene methoden

Country Status (8)

Country Link
US (2) US6541469B2 (de)
EP (1) EP1282624B1 (de)
JP (1) JP2003533527A (de)
AT (1) ATE260918T1 (de)
AU (1) AU2001263329A1 (de)
DE (1) DE60102231T2 (de)
ES (1) ES2214422T3 (de)
WO (1) WO2001087889A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001263329A1 (en) * 2000-05-18 2001-11-26 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
AU2003220190A1 (en) 2002-03-13 2003-09-29 Pharmacia & Upjohn Company Llc Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
US7365078B2 (en) 2004-01-06 2008-04-29 Taisho Pharmaceutical Co., Ltd. Triaza-cyclopenta[cd]indene derivatives
CA2576435A1 (en) * 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
EP1049699B1 (de) 1998-01-28 2004-04-21 Bristol-Myers Squibb Pharma Company Pyrazolotriazine als crf antagonisten
PT1129096E (pt) 1998-11-12 2003-09-30 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
AU2001263329A1 (en) * 2000-05-18 2001-11-26 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto

Also Published As

Publication number Publication date
WO2001087889A1 (en) 2001-11-22
AU2001263329A1 (en) 2001-11-26
US20040014747A1 (en) 2004-01-22
DE60102231T2 (de) 2005-04-14
EP1282624B1 (de) 2004-03-03
US6541469B2 (en) 2003-04-01
DE60102231D1 (de) 2004-04-08
JP2003533527A (ja) 2003-11-11
EP1282624A1 (de) 2003-02-12
US20020032194A1 (en) 2002-03-14
ES2214422T3 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
ATE225349T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DE69908173D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
AU1529402A (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
GB0130347D0 (en) Compounds
ATE430746T1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
BRPI0417943A (pt) antagonistas de receptor de crf e métodos relacionados para essa finalidade
ATE343578T1 (de) Tri- und tetraaza-acenaphthylen-derivate als crf- rezeptor-antagonisten
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
MXPA04006571A (es) Derivado de pirimidina biciclica fusionada.
ATE250058T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
DE60102231D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
EA200400822A1 (ru) Производные 3,4-дигидро-1h-изохинолин-2-ила
DE602004012318D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren
ATE364594T1 (de) (4-acylaminopiperidin-1-yl)acetamide als neurokininantagonisten
YU39603A (sh) Jedinjenja piperazinilpirazina kao antagonisti serotonin 5-ht2 receptora

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties